Introduction {#sec0005}
============

Hyperthyroidism complicates approximately 0.1--0.4% of pregnancies, with 85--90% of cases due to Graves' disease (GD), an autoimmune disorder caused by an immunoglobulin G antibody that stimulates the thyroid-stimulating hormone (TSH) receptor \[[@bib0005]\]. If not properly managed, it can result in severe maternal, fetal, and neonatal morbidity and mortality. Maternal complications include abortion, pre-eclampsia, preterm labor, placental abruption, congestive heart failure, and thyroid storm \[[@bib0010]\].

The fetus of a pregnant woman with GD is at risk of thyroid dysfunction from the transplacental transfer of the TSH receptor antibody. A pregnant woman with GD is usually treated with antithyroid drugs (ATDs), but ATDs can pass through the placenta, and high doses can cause fetal hypothyroidism \[[@bib0015]\].

Fetal goiter is an abnormal enlargement of the fetal thyroid gland, and it indicates thyroid dysfunction \[[@bib0020]\]. Untreated fetal goiters are often associated with perinatal and postnatal complications caused by the goiters themselves and the attendant thyroid dysfunction. Prenatal management can prevent these adverse outcomes, but systematic verifications of these interventions are limited, and the risk-to-benefit ratio is controversial. This review summarizes the current knowledge about fetal goiter associated with maternal GD and evaluates the most significant new findings regarding its in utero and peripartum management.

Fetal goiter associated with maternal Graves' disease {#sec0010}
=====================================================

Fetal goiter is found in 19% of the fetuses carried by mothers with GD \[[@bib0025]\]. Fetal goiter associated with maternal GD can result from either fetal hyperthyroidism or hypothyroidism. Fetal goiter is a very rare phenomenon; indeed, the incidence of goitrous hypothyroidism is approximately one per 40,000 live births, and goiter is found in only 10%--15% of all cases of congenital hypothyroidism \[[@bib0030],[@bib0035]\]. The incidence of goitrous hyperthyroidism is unknown.

After 20 weeks of gestation, the fetal TSH receptors become responsive to TSH. Maternal thyroid-stimulating antibodies (TSAbs) cross the placenta and can overstimulate the fetal thyroid, causing hyperthyroidism and goiter \[[@bib0040]\]. Fetal goitrous hypothyroidism may occur in the presence of thyroid-blocking antibodies (TBAbs) or when high-dose ATDs are administered to the mother. As fetal hypothyroidism caused by TBAbs is extremely rare \[[@bib0040]\], fetal hypothyroidism accompanied by maternal GD is commonly caused by the excessive placental transfer of maternal ATDs \[[@bib0015]\]. Before the onset of fetal thyroid function during midgestation, the fetus relies on the transplacental passage of maternal thyroid hormone \[[@bib0040]\]; therefore, there is no need to consider any direct effects of ATDs. After midgestation, the maternal thyroxine (T~4~) supply remains extremely important to the fetus, but the transfer of maternal T~4~ may not be able to fully compensate for the blockage of fetal thyroid hormone synthesis by maternal ATDs. Consequently, the thyroid lobes enlarge, which is likely caused by the hyperstimulation of the tissue by the increased levels of fetal TSH in response to fetal thyroid insufficiency. Fetal goiter can cause complications that are attributable either to the goiter itself, for example, the mechanical effects of the neck mass, or to the hormonal abnormalities. In utero, a very large goiter may cause esophageal compression with secondary polyhydramnios or tracheal compression, both of which are compounded by dystocia caused by neck hyperextension \[[@bib0045]\]. At birth, tracheal compression caused by the enlarged thyroid gland can lead to respiratory distress and death \[[@bib0045]\].

Fetal hyperthyroidism can cause fetal growth restriction (FGR) which is accompanied by accelerated bone maturation, goiter development, and craniosynostosis. Thyrotoxicosis, comprising tachycardia, cardiac failure, and hydrops, can occur, which may cause premature birth, intrauterine or perinatal death, or serious neurological sequelae \[[@bib0050]\]. Fetal hypothyroidism is associated with retarded skeletal development, mental retardation, hearing defects, poor visuomotor abilities, delayed speech and language development, and poor attention and memory skills \[[@bib0055]\]. Despite immediate postnatal evaluations and thyroid hormone replacement, some neurological abnormalities may persist. The degree of neurological impairment has been associated with the severity of the hypothyroidism and the age at diagnosis. The treatment of fetal hypothyroidism without a goiter remains controversial, because it is difficult to diagnose, and it is unclear whether the condition affects a child's prognosis \[[@bib0015],[@bib0045]\]. Since the presence of a goiter clearly indicates serious fetal thyroid dysfunction, prenatal identification and treatment of goiter are recommended \[[@bib0060]\].

Diagnosis of fetal goiter and thyroid status {#sec0015}
============================================

The early detection of fetal goiter and appropriate evaluation of fetal thyroid dysfunction are crucial to prevent adverse outcomes in fetuses and neonates.

Fetal ultrasonography {#sec0020}
---------------------

As the fetal thyroid gland can be accurately assessed using serial ultrasonography (US) at 20--36 weeks of gestation, a fetal goiter can be diagnosed using US during the second or third trimester. On US, a fetal goiter appears as a homogeneous, symmetrical, and hyperechogenic mass in the anterior neck region, and it is defined as a fetal goiter when the thyroid gland's width and circumference exceed the 95th percentile for the gestational age \[[@bib0020]\]. When a goiter is detected, it is important to document its size and vascularity, and more importantly, the size of the trachea and the presence of fetal swallowing should be noted.

In fetuses with goiters, determining whether the cause is fetal hypothyroidism or hyperthyroidism is the main clinical challenge \[[@bib0015]\]. On US, goiter vascularization, the fetal heart rate, bone maturation, and fetal movement differ appreciably according to the presence of fetal hyperthyroidism or hypothyroidism. For example, using the Doppler technique, an increased blood flow throughout the gland is linked to fetal hyperthyroidism, whereas an increased blood flow at the periphery of the gland has been associated with fetal hypothyroidism \[[@bib0060]\]. Huel et al. proposed an ultrasound scoring system, based on the color Doppler pattern (peripheral/central vascularization), fetal heart rate (tachycardia/normal heart rate), bone maturation (early/late), and fetal movements (intense/normal), to predict fetal thyroid function in cases of fetal goiter \[[@bib0025]\]. Although the researchers correctly distinguished 36 cases of fetal hypothyroidism from hyperthyroidism using this scoring system, some inconsistency remains, and its practical applicability is poor.

Fetal magnetic resonance imaging {#sec0025}
--------------------------------

Fetal magnetic resonance imaging (MRI) complements US examinations by helping to differentiate goiters from cervical tumors, delineate a goiter's full extent \[[@bib0065]\], and to assess the levels by which a goiter obstructs the trachea and esophagus in the presence of massive polyhydramnios \[[@bib0070]\]. Fetal MRI also helps differentiate the status of the thyroid by analyzing the T1 and T2 signals. A fetal thyroid gland can be identified as a hyperintense structure in the neck on T1-weighted images, which can differentiate goiters from other neck masses more readily than US \[[@bib0075]\]. Moreover, the intensity of the thyroid T2 signals varies with the functional status, because it correlates with the iodine concentration; hence, a thyroid gland with a high iodine concentration has a low signal intensity, and a gland with a low iodine concentration has a high signal intensity \[[@bib0080]\]. As a normal thyroid gland's signal intensity is as low as that of muscle on T2-weighted images, the presence of a signal that is higher than that associated with muscle signifies a hypofunctioning thyroid gland \[[@bib0080]\]. [Table 1](#tbl0005){ref-type="table"} summarizes our review of previous reports that describe MRI findings from fetal goiters between 2000 and 2018 \[[@bib0065],[@bib0075],[@bib0085], [@bib0090], [@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135]\]. Without a maternal thyroid gland abnormality, fetal hypothyroidism is characterized by a fetal thyroid gland that shows a hyperintense signal on T2-weighted images. In contrast, in the presence of maternal GD, there might be no relationship between the signal intensity and fetal thyroid abnormalities on T2-weighted images. Therefore, MRI may not correspond to expectations regarding the discrimination of fetal hyperthyroidism and hypothyroidism in the presence of maternal GD.Table 1Intrauterine magnetic resonance imaging for fetuses with goiters, 2000--2018.Table 1ReferenceMaternal thyroid diseaseAntithyroid drugsMaternal thyroid statusGA at MRI (weeks)Signal intensityFetal thyroid statusCommentsT1-weighted imageT2-weighted imageHighIsoMiyata, et al. \[[@bib0085]\]GDYesHyper36N/AHighHypoHarreld, et al. \[[@bib0090]\]GDYesN/A34HighLowN/AMatsumoto, et al. \[[@bib0095]\]GDYesEuthyroid34N/AHighHyperKanai, et al. \[[@bib0100]\]GDYesEuthyroid36HighLowHypoOguma, et al. \[[@bib0105]\]GDYesHyper32HighLowHypoOvercash, et al. \[[@bib0110]\]HypoNoHypo29N/AHighN/AMatsumoto, et al. \[[@bib0115]\]NoNoEuthyroid29HighN/AHypoKondoh, et al. \[[@bib0075]\]NoNoN/A32HighHighHypoOhira, et al. \[[@bib0120]\]NoNoHypo28N/AHighHypoMaternal TSBAbMiyamoto, et al. \[[@bib0125]\]NoNoEuthyroid37HighHighHypoMaternal iodine excessInoue, et al. \[[@bib0130]\]NoNoEuthyroid29HighHighHypoNeto, et al. \[[@bib0135]\]NoNoEuthyroid34N/AHighN/A[^1]

Amniotic fluid sampling {#sec0030}
-----------------------

Amniocentesis to evaluate the TSH levels in the amniotic fluid may be useful to check fetal thyroid metabolism, and it is less technically demanding and safer than cordocentesis. Previous reports indicate that the amniotic fluid TSH levels reflect fetal rather than maternal thyroid function, because TSH does not cross the placenta \[[@bib0140]\]. Moreover, reference ranges have been established for thyroid hormone levels in the amniotic fluid \[[@bib0145]\]. These data may support the use of amniotic fluid analysis to diagnose fetal hypothyroidism; however, the value of amniotic fluid analysis alone in the presence of fetal thyroid dysfunction is controversial. Discrepancies between the intra-amniotic and neonatal blood TSH levels have been described, and the relative maternal and fetal contributions to the hormone levels in the amniotic fluid are unclear \[[@bib0140]\]. Indirect quantification based on the thyroid hormone levels in the amniotic fluid does not accurately reflect the function of the fetal thyroid gland, and it only enables the assessment of dynamic changes. Hence, the TSH levels in the amniotic fluid may have some diagnostic value for fetuses with severe hypothyroidism, especially when cordocentesis is not available.

Fetal blood sampling {#sec0035}
--------------------

Cordocentesis, which is the gold standard diagnostic method \[[@bib0045]\], enables direct measurements of the fetal thyroid hormone levels and accurate determinations of the fetal thyroid status because normal reference values for fetal thyroid function have been established \[[@bib0040],[@bib0150]\]. However, the minor and major complications associated with this invasive procedure should be stressed; these include fetal bleeding, infections, bradycardia, premature rupture of membranes, and death, which occur in 0.5--9.0% of patients \[[@bib0140]\]. Cordocentesis may not be required for all patients, and it should only be undertaken in specialist centers. The European Society for Paediatric Endocrinology consensus guidelines on the screening, diagnosis, and management of congenital hypothyroidism recommend using cordocentesis rather than amniocentesis to assess fetal thyroid function \[[@bib0155]\].

Intrauterine treatment of fetal goiter {#sec0040}
======================================

Regardless of whether hyperthyroidism or hypothyroidism is present, the treatment of a large fetal goiter is essential, because tracheal obstruction could cause neonatal death and fetal neck hyperextension could cause mechanical issues during delivery.

Treatment of fetal goiter caused by hyperthyroidism {#sec0045}
---------------------------------------------------

A fetus that has hyperthyroidism benefits directly from the administration of ATDs to the mother, because ATDs cross the placenta and act on the fetal thyroid gland. A mother with hyperthyroidism who receives ATDs will usually require an increased ATD dose. If a euthyroid mother who is not receiving medication is carrying a fetus with a goiter, it is usually possible to treat the mother with ATDs. Although propylthiouracil (PTU) and methimazole (MMI) control hyperthyroidism similarly, PTU is a first-line drug for the treatment of fetal hyperthyroidism, and its use as the initial treatment is preferred, because MMI causes a series of malformations when it is used during the first trimester \[[@bib0160]\]. The resolution of fetal tachycardia has been used to indicate the successful intrauterine medical treatment of fetal hyperthyroidism. Nonetheless, ATDs may expose a fetus to the risk of hypothyroidism; therefore, ATDs should be administered at low doses that maintain the fetal heart rate at 140 beats/min \[[@bib0040]\]. If the mother develops hypothyroidism during this treatment, levothyroxine (L-T~4~) is added, because very little T~4~ is transferred across the placenta.

A hyperthyroid fetus that required urgent treatment and was administered potassium iodide in combination with ATDs has been described with favorable results \[[@bib0095]\]. Potassium iodide acutely inhibits hormonal secretions within hours of its administration to hyperthyroid patients, and there are few side-effects. However, additional fetal monitoring is advised, because administering iodine to mothers may cause fetal and neonatal hypothyroidism and goiters \[[@bib0160]\]. Beta-adrenergic blocking agents, including propranolol, can be used in severe cases. As most symptoms of fetal thyrotoxicosis, including tachycardia, are mediated by increased adrenergic responses, beta-blockers can ameliorate these symptoms within a few hours of their administration; however, their use requires caution because of their adverse effects, including FGR, prolongation of labor, neonatal bradycardia, hypotension, hypoglycemia, and prolonged jaundice \[[@bib0160]\].

Treatment of fetal goitrous hypothyroidism {#sec0050}
------------------------------------------

The treatment of fetal goitrous hypothyroidism requires optimization of the maternal thyroid status, which includes reducing or discontinuing treatment with ATDs \[[@bib0015]\], followed by conservative management involving neonatal administration of [l]{.smallcaps}-T~4~ \[[@bib0045],[@bib0070]\]. In contrast to fetal hyperthyroidism, fetal hypothyroidism cannot be treated by administering [l]{.smallcaps}-T~4~ to the mother because the placental transfer of maternal T~4~ is minimal \[[@bib0045]\]. Hence, fetal hypothyroidism can only be treated by directly administering thyroid hormone to the fetal blood vessels or muscles, or to the amniotic fluid. Injecting the fetus itself is associated with the risk of injury and may require several puncture attempts. Injecting [l]{.smallcaps}-T~4~ intra-amniotically represents a safer and simpler management option compared with other methods, and it has a long treatment interval \[[@bib0165]\]; the fetus swallows and ingests the [l]{.smallcaps}-T~4~, and the fetal thyroid function normalizes as a consequence of the higher serum [l]{.smallcaps}-T~4~ levels and reduced TSH levels, which may be beneficial to the developing fetal brain \[[@bib0045]\]. The simultaneous decrease in the size of the goiter should reduce the obstetric risks at delivery \[[@bib0165]\]. To our knowledge, the first case of intra-amniotic [l]{.smallcaps}-T~4~ injections associated with maternal ATD overtreatment was reported in 1980 \[[@bib0170]\]. Since then, several intra-amniotic [l]{.smallcaps}-T~4~ injections have been performed; however, most data that describe the prenatal treatment of fetuses with goitrous hypothyroidism are from anecdotal case reports. The findings from one retrospective cohort study of 12 patients with fetal goitrous hypothyroidism support the benefits associated with reducing goiter sizes \[[@bib0175]\]; however, only two of the patients in this study had normal serum T~4~ levels at birth. The findings from a recent systematic review showed that six of 22 neonates (27%) had hypothyroidism after prenatal maternal ATD dose reductions and intra-amniotic [l]{.smallcaps}-T~4~ injections \[[@bib0015]\]. Hence, this effective treatment does not always prevent hypothyroidism after birth.

Unanswered questions remain that include when treatment should begin, [l]{.smallcaps}-T~4~ dosing, and the interval and frequency of administration. As few pharmacokinetic data portray the fetal uptake and absorption of [l]{.smallcaps}-T~4~ from the amniotic fluid, different treatment regimens have been described. [Table 2](#tbl0010){ref-type="table"} summarizes 22 case reports that describe intra-amniotic [l]{.smallcaps}-T~4~ injections for fetal goitrous hypothyroidism in maternal GD \[[@bib0030],[@bib0045],[@bib0085],[@bib0170],[@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210], [@bib0215], [@bib0220], [@bib0225], [@bib0230], [@bib0235], [@bib0240], [@bib0245], [@bib0250]\]. The median (interquartile range) dose, frequency, interval, and gestational age at the initiation of therapy were 250 (128--350) μg, 3 (2--4) times, 1 (1--2) weeks, and 32 (29--34) weeks of gestation, respectively. The critical gestational age at which therapy must be initiated should be determined clinically by balancing the risk of not treating the condition against the risk of prematurity at that gestational age. While some clinicians believe that the hormonal deficiency should be corrected quickly to prevent negative effects on the fetal brain and have initiated treatment at as early as 20 weeks of gestation, other clinicians have initiated treatment at as late as 37 weeks of gestation \[[@bib0045],[@bib0165]\]. Regarding the fetal outcomes, intra-amniotic [l]{.smallcaps}-T~4~ injections reversed the laboratory evidence that indicated hypothyroidism, resolved the fetal goiters, and prevented asphyxia and respiratory distress in all except one of the patients. Moreover, all except one of the patients grew and developed normally after birth, but the follow-up period was no more than 4 years. Whether prenatal [l]{.smallcaps}-T~4~ treatment improves neurodevelopmental outcomes remains a matter of debate. In this series, most of the patients did not experience any adverse events, but two babies were born prematurely and chorioamnionitis occurred in one patient. Another publication describes preterm labor, FGR, chorioamnionitis, and fetal death following intra-amniotic [l]{.smallcaps}-T~4~ injections \[[@bib0070]\]. Moreover, a T~4~ overdose may cause fetal thyrotoxicosis.Table 2. Previous cases of fetal goiter in maternal Graves' disease treated with intraamniotic thyroxine administration.Table 2TreatmentReferenceMaternal ATD and dose (mg/day)GA at diagnosis of fetal goiter (WGA)Fetal blood thyroid function\
at treatment completionATDs reductionIntraamniotic LT~4~ administrationGoiter reductionComplicationGA at birth (WGA) and delivery modeBirth weight (g)Birth asphyxiaRespiratory distressNeonatal blood thyroid\
function at birthDevelopmental delayTSH (mIU/L)Free T~4~ (pmol/L)Total T~4~ (nmol/L)GA at initiation (WGA)Dose (μg/dose)FrequencyInterval (week)TSH (mIU/L)Free T~4~ (pmol/L)Total T~4~ (nmol/L)Weiner, et al. \[[@bib0170]\]PTU, 40030N/AN/AN/AYes342001--YesNo36, CS2891NoYes (TTN)17.9N/A100N/ADavidson, et al. \[[@bib0045]\]PTU, 4502825N/A41Yes3525031YesNo38, VD2960NoNo15.8N/A81NoNoia, et al. \[[@bib0180]\]PTU, 2002617N/A62N/A362501--YesNoTerm, VD3639NoNo2.824.4188NoVan Loon, et al. \[[@bib0185]\]PTU, 60033\>503.5N/AYes3325041YesNo39, VD3090NoNo158.8N/ANoHadi, et al. \[[@bib0190]\]PTU, 6003132N/A45Yes3325031YesNo37, VD2980NoYes15N/A116NoHadi, et al. \[38\]PTU, 3002725N/A37Yes2923041YesPreterm birth33, VD2210NoNo17N/A103NoNicolini, et al. \[[@bib0195]\]PTU, 3002416401N/AYes2560051--6YesNo38, VD1830NoNo96.5N/A145NoBruner, et al. \[[@bib0200]\]PTU, 100283783.2\<16Yes29250--50051YesPreterm birth35, VD2413NoNoNormalNormalNormalNoBruner, et al. \[[@bib0200]\]PTU, 15031324N/A\<16Yes322501--YesPreterm birth32, CS1723NoNoN/AN/AN/ANoMaragliano, et al. \[[@bib0205]\]PTU, 2503115,746N/AYes34250--50022YesNo39, CS2650NoNo\<0.111.8N/ANoOkumura, et al. \[[@bib0210]\]PTU, 3002598.6511.6N/AYes3225023YesNo39, VD2630NoNoNormalNormalNormalNoYanai, et al. \[[@bib0215]\]PTU, 20029389.8N/AYes2920031YesNo36, VD3000NoNoNormalNormalNormalNoNath, et al. \[[@bib0220]\]PTU, 1002323.61N/AN/AYes3050022YesNo36, CSN/ANoNoNormalNormalNormalNoMiyata, et al. \[[@bib0085]\]PTU, 30036993.7N/ANo3730021YesNo38, CS3042NoNo3318N/ANoLassen, et al. \[[@bib0225]\]MMI, 303129.910.7N/AYes3270 μg/kg/EFW41YesNo36, CS2880NoYes (RDS)8.314.2N/ANoCorral, et al. \[[@bib0030]\]PTU, 300244801.818.5Yes3450041YesNo37, CS3500NoNo2618149YesKoyuncu, et al. \[[@bib0230]\]PTU, 2003069.95.9N/ANo302501--NoPreterm birth30, CS1200YesYes (RDS)39.210.7N/ANoBliddal, et al. \[[@bib0235]\]PTU, 20023\>2003.4N/AYes2350--10061YesNo40, VD4100NoNo5.4N/AN/ANoBliddal, et al. \[[@bib0235]\]MMI, 202134.513.8N/AYes2555--15021YesNo40, CS3630NoNo0.740.4N/ANoMunoz, et al. \[[@bib0240]\]PTU, 60023N/AN/AN/ANo29200--40024YesPreterm birth\
FGR35, CS1880NoNoN/AN/AN/ANoKim, et al. \[[@bib0245]\]Radioactive303906.7N/A--30200--40021--4YesNo38, VD2495NoNo11.817.9N/ANoKobayashi, et al. \[[@bib0250]\]PTU, 1503297.86.1N/AYes3530021YesNo37, CS3224NoNo42.517.9N/ANo[^2]

As a possible alternative, intra-amniotic [l]{.smallcaps}-tri-iodothyronine (L-T~3~) injections given either alone or in combination with [l]{.smallcaps}-T~4~, have been administered successfully \[[@bib0165],[@bib0255]\]. As the effects of [l]{.smallcaps}-T~3~ on the fetus begin within 4--8 h of its administration, intra-amniotic [l]{.smallcaps}-T~3~ injections may reduce the size of the goitrous mass faster and at a lower dose than [l]{.smallcaps}-T~4~ injections. On the other hand, more frequent intra-amniotic [l]{.smallcaps}-T~3~ injections may be required to maintain a consistent effect because the half-lives of [l]{.smallcaps}-T~3~ and [l]{.smallcaps}-T~4~ are 1--2 days and 6--7 days, respectively \[[@bib0165]\]. The optimal dosing regimen for [l]{.smallcaps}-T~3~ remains unclear.

Limited literature reviews have evaluated the different administration routes for [l]{.smallcaps}-T~4~, including umbilical cord injections or fetal intramuscular injections \[[@bib0030],[@bib0260]\]. These methods should be considered for a patient whose ability to swallow is critically impaired, because the goitrous mass is causing extreme pressure on the esophagus. The wide variety of approaches to treatment exemplifies the lack of guidelines, and no systematic studies have been undertaken to date.

Peripartum management of fetal goiter {#sec0055}
=====================================

The major problem regarding fetuses with goiters is how to manage their delivery when intrauterine treatment fails; however, there has been no generally accepted strategy for the management of childbirth. As the peripartum prognosis is mainly related to the risk of dystocia at delivery as a consequence of cervical deflection in such cases, cesarean delivery is highly recommended \[[@bib0240]\]. In all cases, the pediatric team must be informed of the goiter diagnosis to optimize the prevention of potential serious perinatal mechanical complications.

For a patient in whom a fetal goiter may be causing airway obstruction, a cesarean delivery with ex utero intrapartum treatment (EXIT) should be considered. This procedure permits access to the fetal airway via intubation, laryngoscopy, or bronchoscopy, and, eventually, tracheostomy while the fetus remains under placental support, and can prevent respiratory insufficiency after birth, and it has significantly reduced the mortality of patients with large neck masses \[[@bib0265]\]. However, to the best of our knowledge, only eight cases involving EXIT for fetal goiter have been reported to date, although the detailed clinical course in each case was not described ([Table 3](#tbl0015){ref-type="table"}) \[[@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290], [@bib0295], [@bib0300], [@bib0305]\]. Meanwhile, EXIT is accompanied by difficulties associated with preserving an adequate blood flow through the umbilical cord, protecting the placenta, and avoiding uterine contractions to ensure that there is sufficient time to establish an airway. Although there have been few fetal complications directly related to EXIT, the partially delivered fetus should be directly monitored with pulse oximetry and continuous echocardiography to detect fetal bradycardia and decreased myocardial contractility \[[@bib0265]\]. Regarding maternal complications, an important concern is bleeding, which is usually associated with uterine atony, related to the administration of high-dose tocolytic drugs or excess time spent establishing the fetal airway during the procedure \[[@bib0310]\]. Therefore, careful coordination among a multidisciplinary team that includes obstetricians (usually perinatologists), neonatologists, pediatric surgeons, otolaryngologists, and anesthesiologists is required to achieve successful outcomes from EXIT \[[@bib0265]\].Table 3. Reported cases in which the ex utero intrapartum treatment procedure was performed in fetus with goiter.Table 3ReferenceMaternal thyroid diseaseCause of fetal goiterIntrauterine treatmentGestational age at delivery (weeks)EXIT procedureTime to airwayApgar score (1 min/5 min)Maternal or neonatal complicationNeonatal outcomeKlee, et al. \[[@bib0270]\]Graves' diseaseHypothyroidismIntraamniotic T~4~ injection38Endotracheal intubationN/A8 / 9NoAliveFink, et al. \[[@bib0275]\]Graves' diseaseN/ANo36Endotracheal intubation9 min3 / 8N/AAliveHarreld, et al. \[[@bib0280]\]Graves' diseaseHypothyroidismNo36N/AN/A3 / 8Stridor in the neonateAliveSriram, et al. \[[@bib0285]\]UnknownHypothyroidismNo37Endotracheal intubationN/AN/A / 8NoAliveNiiya, et al. \[[@bib0290]\]UnknownHypothyroidismNo35Endotracheal intubation6 minN/ANoAliveWhited, et al. \[[@bib0295]\]N/AN/AN/A36Endotracheal intubation9 minN/ANoAliveScott, et al. \[[@bib0300]\]N/AN/AN/A34N/AN/AN/ANoAliveKornacki, et al. \[[@bib0305]\]UnknownHypothyroidismIntraamniotic T~4~ injection37Endotracheal intubationN/A9 / 9NoAlive[^3]

An innovative alternative to EXIT is fetal endoscopic tracheal intubation. The procedure involves fetal tracheoscopy and the subsequent insertion of an intrauterine orotracheal cannula under ultrasound guidance. This procedure ensures fetal tracheal permeability before delivery. However, to date, only two publications describe this new procedure that was performed on patients with large neck masses but not goiters \[[@bib0315],[@bib0320]\].

Summary and recommendations {#sec0060}
===========================

The potential morbidity and mortality associated with a fetal goiter warrants a complete evaluation of the fetal thyroid status. This can be achieved through a combination of imaging methods, such as ultrasound examinations, which include color Doppler imaging, and MRI, and cordocentesis or amniocentesis to measure the fetal thyroid hormone levels. However, the thyroid hormone levels in the amniotic fluid may not accurately reflect fetal thyroid function. Regarding the treatment of fetal goitrous hypothyroidism, administering thyroid hormone intra-amniotically shrinks goiters and results in good developmental outcomes. In addition, when intrauterine treatment fails and a fetal goiter causes airway obstruction, intrapartum management, including EXIT, is required; however, no guidelines are available currently. A large-scale, well-designed study is necessary for monitoring therapeutic efficacy and long-term prognosis. For now, intrauterine and intrapartum treatments should be reserved for selected patients who are at a high risk of complications, and they should only be conducted by physicians with experience in intrauterine and peripartum care and related procedures.
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[^1]: GA: gestational age; MRI: magnetic resonance imaging; GD: Graves' disease; N/A: not available; Hypo: hypothyroidism; Hyper: hyperthyroidism; Iso: isointense; TSBAb: thyroid stimulation-blocking antibody.

[^2]: ATD: antithyroid drug; GA: gestational age; WGA: weeks of gestation; TSH: thyroid-stimulating hormone; T~4~: thyroxine; LT~4~: levothyroxine; PTU: propylthiouracil; MMI: methimazol; N/A: not available; EFW: estimated fetal weight; FGR: fetal growth restriction; CS: cesarean delivery; VD: vaginal delivery; TTN: transient tachypnea of the newborn; RDS: respiratory distress syndrome. Reference ranges of fetal thyroid function according to Thorpe-Beeston et al. are: TSH: 2--12  mIU/L; Free T~4~: 5.1--27 pmol/L; T~4~: 15--125 nmol/L \[[@bib0120]\]. Reference ranges of neonatal thyroid function according to Fisher are: TSH: 1--39 mIU/L; free T~4~: 28--68 pmol/L; T~4~: 142--277 nmol/L \[[@bib0050]\].

[^3]: EXIT: ex utero intrapartum treatment; N/A: not available; T~4~: thyroxine.
